A Phase 1b Study of the Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Trial Profile

A Phase 1b Study of the Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Citarinostat (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Acetylon Pharmaceuticals; Celgene Corporation
  • Most Recent Events

    • 01 Nov 2017 Planned End Date changed from 31 Dec 2017 to 11 Oct 2018.
    • 01 Nov 2017 Planned primary completion date changed from 31 Dec 2017 to 11 Oct 2018.
    • 18 Oct 2017 Results (n=13, data cut off: 16 June 2017) presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top